ipodate has been researched along with Graves Disease in 19 studies
Ipodate: Ionic monomeric contrast media. Usually the sodium or calcium salts are used for examination of the gall bladder and biliary tract. (From Martindale, The Extra Pharmacopoeia, 30th ed, p704)
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Consecutive patients with hyperthyroidism caused by Graves' disease or by multinodular toxic goiter were randomized to be treated with high-dose propylthiouracil (PTU) to block D1, PTU plus KI, or PTU plus sodium ipodate to additionally block D2." | 9.12 | Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. ( Christensen, SE; Helleberg, K; Laurberg, P; Nielsen, S; Pedersen, KM; Seefeldt, T; Vestergaard, H, 2007) |
| "We describe the effect of administration of repeated doses of sodium ipodate in a newborn infant with hyperthyroidism due to transient Graves' disease." | 7.67 | Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. ( Filetti, S; Fisher, DA; Karpman, BA; Rapoport, B, 1987) |
| "A dose (3 g) of sodium ipodate used routinely in oral cholecystography caused a fall in serum 3,5,3'-triiodothyronine and a rise in serum 3,3',5'-triiodothyronine in three patients taking thyroxine (T4), four euthyroid subjects,and four hyperthyroid patients." | 7.66 | Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. ( Bennett, LR; Chopra, IJ; Solomon, DH; Wu, SY, 1978) |
| "No ipodate was discontinued in the eight patients who did not respond, and they were then treated with MMI." | 5.29 | Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease. ( Bianconi, L; Braverman, LE; Gardini, E; Minelli, R; Roti, E, 1993) |
| "Patients with thyrotoxic Graves' disease were treated daily for 10 d with 1 g sodium ipodate, an iodine rich X-ray contrast agent which impairs outer ring (5'-) deiodination of T4 to T3, or with 12 drops of a saturated solution of potassium iodide (SSKI)." | 5.27 | Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease. ( Barlli, AL; Braverman, LE; D'Amato, L; Gardini, E; Gnudi, A; Manfredi, A; Montermini, M; Robuschi, G; Roti, E; Salvi, M, 1985) |
| "Consecutive patients with hyperthyroidism caused by Graves' disease or by multinodular toxic goiter were randomized to be treated with high-dose propylthiouracil (PTU) to block D1, PTU plus KI, or PTU plus sodium ipodate to additionally block D2." | 5.12 | Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. ( Christensen, SE; Helleberg, K; Laurberg, P; Nielsen, S; Pedersen, KM; Seefeldt, T; Vestergaard, H, 2007) |
| "We describe the effect of administration of repeated doses of sodium ipodate in a newborn infant with hyperthyroidism due to transient Graves' disease." | 3.67 | Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. ( Filetti, S; Fisher, DA; Karpman, BA; Rapoport, B, 1987) |
| "A dose (3 g) of sodium ipodate used routinely in oral cholecystography caused a fall in serum 3,5,3'-triiodothyronine and a rise in serum 3,3',5'-triiodothyronine in three patients taking thyroxine (T4), four euthyroid subjects,and four hyperthyroid patients." | 3.66 | Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. ( Bennett, LR; Chopra, IJ; Solomon, DH; Wu, SY, 1978) |
| "No ipodate was discontinued in the eight patients who did not respond, and they were then treated with MMI." | 1.29 | Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease. ( Bianconi, L; Braverman, LE; Gardini, E; Minelli, R; Roti, E, 1993) |
| " Its advantages over conventional therapy are a rapid fall in thyroid hormones and control of symptoms with a simple dosage regime." | 1.28 | Resistant hyperthyroidism induced by sodium iopodate used as treatment for Graves' disease. ( Caldwell, G; Errington, M; Toft, AD, 1989) |
| "Patients with thyrotoxic Graves' disease were treated daily for 10 d with 1 g sodium ipodate, an iodine rich X-ray contrast agent which impairs outer ring (5'-) deiodination of T4 to T3, or with 12 drops of a saturated solution of potassium iodide (SSKI)." | 1.27 | Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease. ( Barlli, AL; Braverman, LE; D'Amato, L; Gardini, E; Gnudi, A; Manfredi, A; Montermini, M; Robuschi, G; Roti, E; Salvi, M, 1985) |
| " We conclude that 1) ipodate (500 mg daily) reduces serum T4 and T3 levels as fast and as much as does the 1-g daily dose studied previously; 2) long term use (for 23-31 weeks) of ipodate for the treatment of Graves' hyperthyroidism is clinically feasible; no adverse effects occurred during or after ipodate treatment; and 3) RAI uptake returns to pretreatment levels as early as 7 days after the discontinuation of ipodate." | 1.27 | Long term treatment of Graves' hyperthyroidism with sodium ipodate. ( Bian, TY; Chopra, IJ; Huang, HW; Jeng, CY; Shen, DC; Shian, LR; Solomon, DH; Wu, SY, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (63.16) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laurberg, P | 1 |
| Vestergaard, H | 1 |
| Nielsen, S | 1 |
| Christensen, SE | 1 |
| Seefeldt, T | 1 |
| Helleberg, K | 1 |
| Pedersen, KM | 1 |
| Arteaga, E | 1 |
| López, JM | 1 |
| Rodríguez, JA | 1 |
| Michaud, P | 1 |
| López, G | 1 |
| Sharp, B | 1 |
| Reed, AW | 1 |
| Tamagra, EI | 1 |
| Geffner, DL | 1 |
| Hershman, JM | 1 |
| Wu, SY | 6 |
| Shyh, TP | 1 |
| Chopra, IJ | 5 |
| Solomon, DH | 5 |
| Huang, HW | 2 |
| Chu, PC | 1 |
| Joshi, R | 1 |
| Kulin, HE | 1 |
| Roti, E | 4 |
| Gardini, E | 4 |
| Minelli, R | 1 |
| Bianconi, L | 1 |
| Braverman, LE | 4 |
| Tomaski, SM | 1 |
| Mahoney, EM | 1 |
| Burgess, LP | 1 |
| Raines, KB | 1 |
| Bornemann, M | 1 |
| Johnson, DE | 1 |
| Bennett, LR | 1 |
| Huang, WS | 1 |
| Polk, D | 1 |
| Florsheim, WH | 1 |
| Green, WL | 1 |
| Fisher, DA | 2 |
| Martino, E | 1 |
| Balzano, S | 1 |
| Bartalena, L | 1 |
| Loviselli, A | 1 |
| Sica, V | 1 |
| Petrini, L | 1 |
| Grasso, L | 1 |
| Piga, M | 1 |
| Shen, DC | 2 |
| Shian, LR | 2 |
| Florsheim, W | 1 |
| Berghout, A | 1 |
| Wiersinga, WM | 1 |
| Brummelkamp, WH | 1 |
| Caldwell, G | 1 |
| Errington, M | 1 |
| Toft, AD | 1 |
| Robuschi, G | 3 |
| Montermini, M | 3 |
| Salvi, M | 3 |
| Manfredi, A | 3 |
| Gnudi, A | 3 |
| d'Amato, L | 2 |
| Borciani, E | 1 |
| Negrotti, L | 1 |
| Karpman, BA | 1 |
| Rapoport, B | 1 |
| Filetti, S | 1 |
| Barlli, AL | 1 |
| Bian, TY | 1 |
| Jeng, CY | 1 |
5 trials available for ipodate and Graves Disease
| Article | Year |
|---|---|
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases.
Topics: Adolescent; Adult; Antithyroid Agents; Child; Drug Therapy, Combination; Female; Goiter, Nodular; Gr | 2007 |
Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Autoantibodies; Female; Graves Disease; Humans; Immun | 1991 |
Further studies on the long-term treatment of Graves' hyperthyroidism with ipodate: assessment of a minimal effective dose.
Topics: Adult; Dose-Response Relationship, Drug; Female; Graves Disease; Humans; Hyperthyroidism; Ipodate; M | 1991 |
Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.
Topics: Adult; Blood Pressure; Drug Evaluation; Drug Therapy, Combination; Female; Graves Disease; Heart Rat | 1988 |
Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease.
Topics: Adult; Clinical Trials as Topic; Female; Graves Disease; Humans; Ipodate; Male; Middle Aged; Potassi | 1986 |
14 other studies available for ipodate and Graves Disease
| Article | Year |
|---|---|
Effect of the combination of dexamethasone and sodium ipodate on serum thyroid hormones in Graves' disease.
Topics: Adolescent; Adult; Dexamethasone; Drug Therapy, Combination; Female; Graves Disease; Humans; Ipodate | 1983 |
Treatment of hyperthyroidism with sodium ipodate (oragrafin) in addition to propylthiouracil and propranolol.
Topics: Female; Graves Disease; Humans; Ipodate; Kinetics; Male; Propranolol; Propylthiouracil; Thyroxine; T | 1981 |
Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism.
Topics: Adult; Blood Pressure; Body Weight; Female; Graves Disease; Humans; Ipodate; Kinetics; Male; Middle | 1982 |
Treatment of neonatal Graves' disease with sodium ipodate. A case report.
Topics: Drug Therapy, Combination; Graves Disease; Humans; Infant, Newborn; Infant, Premature, Diseases; Ipo | 1993 |
Sodium ipodate and methimazole in the long-term treatment of hyperthyroid Graves' disease.
Topics: Adult; Autoantibodies; Body Weight; Female; Graves Disease; Heart Rate; Humans; Ipodate; Male; Methi | 1993 |
Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism.
Topics: Adrenergic beta-Antagonists; Adult; Antithyroid Agents; Blood Loss, Surgical; Female; Graves Disease | 1997 |
The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism.
Topics: Adolescent; Adult; Body Weight; Drug Evaluation; Female; Graves Disease; Humans; Ipodate; Male; Midd | 1978 |
Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography.
Topics: Graves Disease; Humans; Hyperthyroidism; Ipodate; Kinetics; Male; Reference Values; Thyroiditis, Aut | 1978 |
Identification of thyroxine-sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay.
Topics: Amniotic Fluid; Analysis of Variance; Female; Graves Disease; Humans; Ipodate; Pregnancy; Propylthio | 1992 |
Sodium ipodate in the preparation of Graves' hyperthyroid patients for thyroidectomy.
Topics: Adult; Body Weight; Female; Graves Disease; Humans; Ipodate; Male; Middle Aged; Preanesthetic Medica | 1989 |
Resistant hyperthyroidism induced by sodium iopodate used as treatment for Graves' disease.
Topics: Adult; Female; Graves Disease; Humans; Hyperthyroidism; Ipodate; Time Factors | 1989 |
Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate.
Topics: Antibodies; Female; Graves Disease; Humans; Hyperthyroidism; Infant, Newborn; Ipodate; Thyroid Gland | 1987 |
Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease.
Topics: Adult; Female; Graves Disease; Humans; Ipodate; Male; Potassium Iodide; Thyroid Hormones; Thyroxine; | 1985 |
Long term treatment of Graves' hyperthyroidism with sodium ipodate.
Topics: Adult; Female; Graves Disease; Humans; Ipodate; Long-Term Care; Male; Middle Aged; Thyroxine; Triiod | 1985 |